scholarly journals The Effect of Donepezil on Sleep and REM Sleep EEG in Patients with Alzheimer Disease: A Double-Blind Placebo-Controlled Study

SLEEP ◽  
2006 ◽  
Vol 29 (2) ◽  
pp. 199-205 ◽  
Author(s):  
Walter André dos Santos Moraes ◽  
Dalva Rollemberg Poyares ◽  
Christian Guilleminault ◽  
Luiz Roberto Ramos ◽  
Paulo Henrique Ferreira Bertolucci ◽  
...  
Keyword(s):  
Alzheimer Disease ◽  
Rem Sleep ◽  
Sleep Eeg ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

5-12-22 A randomized, double-blind, placebo controlled study of idebenone in Alzheimer disease (AD)

1997 ◽  
Vol 150 ◽  
pp. S296
Author(s):  
L. Sabe ◽  
G. Kuzis ◽  
A. García Cuerva ◽  
C. Tiberti ◽  
M.F. Dorrego ◽  
...  
Keyword(s):  
Alzheimer Disease ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

IDEAL: A 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease

Neurology ◽  
2007 ◽  
Vol 69 (Issue 4, Supplement 1) ◽  
pp. S14-S22 ◽  
Author(s):  
B. Winblad ◽  
G. Grossberg ◽  
L. Frolich ◽  
M. Farlow ◽  
S. Zechner ◽  
...  
Keyword(s):  
Alzheimer Disease ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Skin Patch

Double-Blind, Placebo-Controlled Study of Metrifonate, an Acetylcholinesterase Inhibitor, for Alzheimer Disease

1996 ◽  
Vol 10 (3) ◽  
pp. 124-131 ◽  
Author(s):  
Robert E. Becker ◽  
Jerry A. Colliver ◽  
Stephen J. Markwell ◽  
Pamela L. Moriearty ◽  
Latha K. Unni ◽  
...  
Keyword(s):  
Alzheimer Disease ◽  
Acetylcholinesterase Inhibitor ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

A Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole for the Treatment of Psychosis in Nursing Home Patients with Alzheimer Disease

2008 ◽  
Vol 16 (7) ◽  
pp. 537-550 ◽  
Author(s):  
Joel E. Streim ◽  
Anton P. Porsteinsson ◽  
Christopher D. Breder ◽  
René Swanink ◽  
Ronald Marcus ◽  
...  
Keyword(s):  
Nursing Home ◽  
Alzheimer Disease ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Nursing Home Patients

Donepezil Significantly Improves Abilities in Daily Lives of Female down Syndrome Patients with Severe Cognitive Impairment: A 24-Week Randomized, Double-Blind, Placebo-Controlled Trial

2011 ◽  
Vol 41 (1) ◽  
pp. 71-89 ◽  
Author(s):  
Tatsuro Kondoh ◽  
Atsushi Kanno ◽  
Hiroshi Itoh ◽  
Mikiro Nakashima ◽  
Ryoko Honda ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Cognitive Impairment ◽  
Alzheimer Disease ◽  
Controlled Study ◽  
Dramatic Improvement ◽  
Double Blind ◽  
Daily Lives ◽  
Double Blind Placebo ◽  
Mental Functions ◽  
Severe Cognitive Impairment

Objective: Down syndrome (DS) patients share certain neuropathological features with Alzheimer disease patients. A randomized, double-blind, placebo-controlled study was performed to investigate the efficacy and safety of donepezil, an Alzheimer disease drug, for DS patients. Method: Twenty-one DS patients with severe cognitive impairment were assigned to take donepezil (3 mg daily) or a placebo for 24 weeks, and evaluated for activities in daily lives by concisely modified International Classification of Functioning, Disability and Health (ICF) scaling system. Results: ICF scores significantly increased without any adverse effects in the donepezil group in comparison to those in the placebo control. Among the individual functions tested, there was a dramatic improvement in the global mental functions and in specific mental functions. Conclusions: Donepezil may effectively and safely improve overall functioning of DS patients with severe cognitive impairment.

Sign in / Sign up

Export Citation Format

Share Document